Previous 10 | Next 10 |
The following slide deck was published by Otonomy, Inc. in conjunction with this Read more ...
SAN DIEGO, March 05, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that David A. Weber, Ph.D., president and chief executive officer, is scheduled to participat...
Otonomy (OTIC) Q4 2018 Earnings Conference Call March 4, 2019 04:30 PM ET Company Participants Robert H. Uhl - Westwicke Partners David Weber - President, CEO Paul E. Cayer - Chief Financial & Business Officer Conference Call Participants Stacy Ku - Cowen and Company ...
Gainers: OTIC +5.5% . DERM +4.9% . GME +3.9% . SOI +3.2% . CTBB +3.1% . More news on: Otonomy, Dermira, GameStop Corp., Stocks on the move, Read more ...
Otonomy (NASDAQ: OTIC ): Q4 GAAP EPS of -$0.42 beats by $0.06 . More news on: Otonomy, Earnings news and commentary, Healthcare stocks news, , Read more ...
OTIVIDEX™ Phase 3 trial in Ménière’s disease on track for results in first half 2020 OTO-313 Phase 1/2 trial in tinnitus expected to start in second quarter of 2019 OTO-413 Phase 1/2 trial in hearing loss expected to start in third ...
SAN DIEGO, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the fourth quarter and full year 2018 as well as provide ...
NEW YORK, Feb. 13, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Apache Corporation (NYSE:APA), A. O. Smith Corporation (NYSE:AOS), Dia...
SAN DIEGO, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced multiple presentations at the upcoming Association for Research in Otolaryngology (ARO) 42nd A...
If you are of the fallen angel school of biotech investing, Otonomy ( OTIC ) is worth a listen. If you are wary of falling knives, not so much. Although some may see it as an interesting speculation, I am taking a pass on this one for the time being. I set out my thinking below. Back in 2017...
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC) today announced that it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq) indicating that the company’s shares would be suspended from trading on Nasdaq effective at...
SAN DIEGO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC) today announced that the company’s board of directors, after considering strategic options, has approved and adopted a Plan of Liquidation and Dissolution (“Plan of Dissolution”) that would include...